12 Health Care Stocks Moving In Tuesday’s Intraday Session
Gainers PHAXIAM Therapeutics (NASDAQ:PHXM) shares moved upwards by 22.1% to $5.13 during Tuesday’s regular session. The market value…
Dow Falls 100 Points; ISM Services PMI Increases In November
U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 100 points on Tuesday.
The Dow traded down 0.28% to 36,103.52 while the NASDAQ rose 0.32% to 14,230.64. The S&P 500 also fell, dropping, 0.03% to 4,568.46.
US Stocks Down; JM Smucker Posts Upbeat Earnings
U.S. stocks traded lower this morning, with the Nasdaq Composite falling over 50 points on Tuesday.
Following the market opening Tuesday, the Dow traded down 0.23% to 36,120.88 while the NASDAQ fell 0.40% to 14,129.09. The S&P 500 also fell, dropping, 0.30% to 4,556.06.
What’s Going On With Cancer-Focused Replimune Stock Today?
Replimune Group Inc (NASDAQ: REPL) announced results from the primary analysis of the CERPASS trial evaluating RP1 in combination with cemiplimab for locally advanced or metastatic cutaneous
12 Health Care Stocks Moving In Tuesday’s Pre-Market Session
Gainers Allarity Therapeutics (NASDAQ:ALLR) shares rose 44.0% to $0.86 during Tuesday’s pre-market session. The company’s market cap stands…
Replimune Presents Updated Data On RP2 In Uveal Melanoma During Plenary Session At The 20th International Congress Of The Society For Melanoma Research
Treatment with RP2 led to an overall response rate (ORR) of 29.4 percent (5 of 17 patients; one of the responding patients was treated with RP2 monotherapy and four of the responding patients were treated with RP2
8 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums…
Replimune Announces Appointment Of Emily Hill As Chief Financial Officer
Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced the appointment of Emily Hill as Chief Financial
The Latest Analyst Ratings for Replimune Group
Over the past 3 months, 9 analysts have published their opinion on Replimune Group (NASDAQ:REPL) stock. These analysts…
Replimune And Incyte Enter Into Clinical Trial Collaboration And Supply Agreement To Evaluate RP1 And INCB99280 In Patients With Cutaneous Squamous Cell Carcinoma
Initial study in the neoadjuvant setting designed to assess RP1 in combination with the small molecule, oral PD-L1 inhibitor, INCB99280
Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company